Interestingly, a recent study showed that inhibition of SLC1A5/ASCT2 significantly reduced glutamine uptake in a human breast cancer cell line in a subtype‐dependent manner, with suppression of mTOR signaling, cell growth, and cell cycle progression [12]. This evidence concerns the gene SLC1A5 and breast carcinoma.